AHR and myeloid sarcoma: Laquinimod, an oral drug being evaluated for the treatment of MS, attenuates experimental autoimmune encephalomyelitis (EAE) by inducing the generation of Treg cells and suppression of proinflammatory cytokines in an Ahr-dependent fashion [20].